Could a common cough drug help fatty liver?
NCT ID NCT07242222
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether erdosteine, a drug usually used for lung conditions, can help people with nonalcoholic fatty liver disease. Fifty adults with fatty liver will receive either standard care (diet and exercise) or standard care plus erdosteine. Researchers will measure changes in liver fat and scarring over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Erdosteine (an oral drug with antioxidant and anti-inflammatory properties)
- What this could lead to
- If it works, this could point toward a new treatment option for nonalcoholic fatty liver disease, potentially reducing liver fat and preventing scarring.
- What could go wrong
- This is a very early (Phase 1/2) trial with only 50 participants, so results may not be conclusive. The drug is primarily used as a mucolytic, and its effect on the liver is unproven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FATTY LIVER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tanta Unuversity
RECRUITINGTanta, 31527, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a common b vitamin tame fatty liver?
- HIV and fatty liver: a hidden link under the microscope
- Double liver trouble: does having both hepatitis b and fatty liver speed up disease?
- Could a daily dose of citrus fiber tame fatty liver inflammation?
- Liver's Post-Meal secrets could unlock new fatty liver treatments
- Could a probiotic supplement help reverse fatty liver?